C M Verfaillie
Overview
Explore the profile of C M Verfaillie including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
89
Citations
1336
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Nageshappa S, Carromeu C, Trujillo C, Mesci P, Espuny-Camacho I, Pasciuto E, et al.
Mol Psychiatry
. 2015 Sep;
21(2):178-88.
PMID: 26347316
Increased dosage of methyl-CpG-binding protein-2 (MeCP2) results in a dramatic neurodevelopmental phenotype with onset at birth. We generated induced pluripotent stem cells (iPSCs) from patients with the MECP2 duplication syndrome...
2.
Subramanian K, Park Y, Verfaillie C, Hu W
Biotechnol Bioeng
. 2010 Sep;
108(2):364-75.
PMID: 20830682
Many applications of stem cell technologies require a large quantity of cells for which scalable processes of cell expansion and differentiation are essential. Multipotent adult progenitor cells (MAPCs) are adult...
3.
Park Y, Subramanian K, Verfaillie C, Hu W
J Biotechnol
. 2010 Aug;
150(1):131-9.
PMID: 20696191
Many potential applications of stem cells require large quantities of cells, especially those involving large organs such as the liver. For such applications, a scalable reactor system is desirable to...
4.
Verfaillie C, Ploemacher R, Di Persio J, Sutherland R, Serke S, Johnsen H, et al.
Cytotherapy
. 2009 Sep;
1(1):41-9.
PMID: 19746648
No abstract available.
5.
Sancho-Bru P, Najimi M, Caruso M, Pauwelyn K, Cantz T, Forbes S, et al.
Gut
. 2008 Dec;
58(4):594-603.
PMID: 19091822
There has been recent progress in the isolation and characterisation of stem/progenitor cells that may differentiate towards the hepatic lineage. This has raised expectations that therapy of genetic or acquired...
6.
7.
Jongen-Lavrencic M, Salesse S, Delwel R, Verfaillie C
Leukemia
. 2005 Jan;
19(3):373-80.
PMID: 15674360
The mechanism underlying p210(BCR/ABL) oncoprotein-mediated transformation in chronic myelogenous leukemia (CML) is not fully understood. We hypothesized that p210(BCR/ABL) suppresses expression of genes which may explain at least some of...
8.
Salesse S, Dylla S, Verfaillie C
Leukemia
. 2004 Feb;
18(4):727-33.
PMID: 14961028
Chronic myelogenous leukemia (CML) is a malignancy of the human hematopoietic stem cell (HSC) caused by the p210BCR/ABL oncoprotein. Although alternative splicing of pre-mRNA is a critical determinant of a...
9.
Prosper F, Verfaillie C
An Sist Sanit Navar
. 2004 Jan;
26(3):345-56.
PMID: 14716365
One of the fields of medicine that has created the greatest expectations in recent years is cellular therapy with stem cells. The isolation of human embryo cells, the apparent and...
10.
Verfaillie C, Schwartz R, Reyes M, Jiang Y
Ann N Y Acad Sci
. 2003 Jun;
996:231-4.
PMID: 12799301
No abstract available.